Psychosocial and pharmacologic interventions for methamphetamine addiction: protocol for a scoping review of the literature.

Knowledge synthesis Methamphetamine Methamphetamine addiction Methamphetamine use disorder Pharmacologic treatment Psychosocial treatment Scoping review

Journal

Systematic reviews
ISSN: 2046-4053
Titre abrégé: Syst Rev
Pays: England
ID NLM: 101580575

Informations de publication

Date de publication:
24 10 2020
Historique:
received: 03 07 2020
accepted: 04 10 2020
entrez: 25 10 2020
pubmed: 26 10 2020
medline: 25 6 2021
Statut: epublish

Résumé

Methamphetamine use and harms are rising rapidly. Management of patients with methamphetamine use disorder (MUD) and problematic methamphetamine use (PMU) is challenging, with no clearly established best approach; both psychosocial and pharmacologic interventions have been described. Furthermore, given the diversity of individuals that use methamphetamines, there is a need to assess evidence for treatments for subgroups including youths; gay, bisexual, and other men who have sex with men; individuals with mental health comorbidities; and individuals in correction services. Establishing awareness of the messages regarding treatment from recent clinical practice guidelines (CPG) in the field is also of value. The first study objective will be to establish a greater understanding of the methods, populations, and findings of controlled studies for psychosocial and pharmacologic treatments for MUD and PMU. Investigation of this information can help establish the potential for advanced syntheses of the evidence (such as network meta-analysis) to compare therapies for this condition and to identify gaps related to key populations where more primary research is needed. Summarizing the recommendations regarding treatment of MUD/PMU from recent CPGs and systematic reviews will be an important secondary objective. A scoping review will be performed. Using the OVID platform, MEDLINE, Embase, PsycINFO, and relevant Cochrane databases from EBM Reviews will be searched (from databases' inception onwards). Eligibility criteria will include individuals described as having MUD or PMU, with designs of interest including randomized trials, non-randomized trials, and controlled cohort studies with three or more months of follow-up; systematic reviews and CPGs will also be sought. Two reviewers (with support from automation tools) will independently screen all citations, full-text articles, and chart data. Different approaches to handling and summarizing the data will be implemented for each type of study design. Tables and graphics will be used to map evidence sources and identify evidence gaps. This research will enhance awareness of evidence addressing the effects of psychosocial and pharmacologic interventions for MUD/PMU overall and in sub-populations, both in terms of recent CPGs/reviews and primary studies; inspection of the latter will also help establish the feasibility of future syntheses to compare treatments, such as network meta-analysis. SYSTEMATIC REVIEW PROTOCOL REGISTRATION: Open Science Framework ( https://osf.io/9wy8p ).

Sections du résumé

BACKGROUND
Methamphetamine use and harms are rising rapidly. Management of patients with methamphetamine use disorder (MUD) and problematic methamphetamine use (PMU) is challenging, with no clearly established best approach; both psychosocial and pharmacologic interventions have been described. Furthermore, given the diversity of individuals that use methamphetamines, there is a need to assess evidence for treatments for subgroups including youths; gay, bisexual, and other men who have sex with men; individuals with mental health comorbidities; and individuals in correction services. Establishing awareness of the messages regarding treatment from recent clinical practice guidelines (CPG) in the field is also of value. The first study objective will be to establish a greater understanding of the methods, populations, and findings of controlled studies for psychosocial and pharmacologic treatments for MUD and PMU. Investigation of this information can help establish the potential for advanced syntheses of the evidence (such as network meta-analysis) to compare therapies for this condition and to identify gaps related to key populations where more primary research is needed. Summarizing the recommendations regarding treatment of MUD/PMU from recent CPGs and systematic reviews will be an important secondary objective.
METHODS
A scoping review will be performed. Using the OVID platform, MEDLINE, Embase, PsycINFO, and relevant Cochrane databases from EBM Reviews will be searched (from databases' inception onwards). Eligibility criteria will include individuals described as having MUD or PMU, with designs of interest including randomized trials, non-randomized trials, and controlled cohort studies with three or more months of follow-up; systematic reviews and CPGs will also be sought. Two reviewers (with support from automation tools) will independently screen all citations, full-text articles, and chart data. Different approaches to handling and summarizing the data will be implemented for each type of study design. Tables and graphics will be used to map evidence sources and identify evidence gaps.
DISCUSSION
This research will enhance awareness of evidence addressing the effects of psychosocial and pharmacologic interventions for MUD/PMU overall and in sub-populations, both in terms of recent CPGs/reviews and primary studies; inspection of the latter will also help establish the feasibility of future syntheses to compare treatments, such as network meta-analysis. SYSTEMATIC REVIEW PROTOCOL REGISTRATION: Open Science Framework ( https://osf.io/9wy8p ).

Identifiants

pubmed: 33099314
doi: 10.1186/s13643-020-01499-z
pii: 10.1186/s13643-020-01499-z
pmc: PMC7585172
doi:

Substances chimiques

Methamphetamine 44RAL3456C

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

245

Références

BMJ. 1996 Jan 13;312(7023):71-2
pubmed: 8555924
Pharmacopsychiatry. 2017 May;50(3):87-95
pubmed: 28297728
Obstet Gynecol. 2009 Jun;113(6):1285-91
pubmed: 19461424
Int J Evid Based Healthc. 2015 Sep;13(3):141-6
pubmed: 26134548
J Neurosci. 2004 Jun 30;24(26):6028-36
pubmed: 15229250
Trials. 2019 Feb 21;20(1):145
pubmed: 30791944
Rheumatol Int. 2014 Nov;34(11):1489-96
pubmed: 24691560
Res Synth Methods. 2014 Dec;5(4):371-85
pubmed: 26052958
Drug Alcohol Depend. 2018 Nov 1;192:186-192
pubmed: 30266003
Med J Aust. 2009 Feb 16;190(S4):S22-5
pubmed: 19220169
Front Neurosci. 2015 Jan 12;8:445
pubmed: 25628526
Aust Dent J. 2019 Sep;64(3):213-222
pubmed: 31309583
J Med Chem. 2005 Jun 2;48(11):3663-79
pubmed: 15916415
Cochrane Database Syst Rev. 2016 Sep 29;9:CD011866
pubmed: 27684277
MMWR Morb Mortal Wkly Rep. 2006 Mar 17;55(10):273-7
pubmed: 16543881
Trials. 2012 Aug 06;13:132
pubmed: 22867278
PLoS One. 2012;7(12):e49897
pubmed: 23227154
PLoS Med. 2009 Jul 21;6(7):e1000097
pubmed: 19621072
Expert Opin Investig Drugs. 2002 Apr;11(4):491-9
pubmed: 11922858
Cochrane Database Syst Rev. 2011 Oct 05;(10):CD004147
pubmed: 21975742
Syst Rev. 2012 Feb 10;1:10
pubmed: 22587960
Prev Med. 2010 Nov;51(5):421-4
pubmed: 20728466
Gend Med. 2010 Oct;7(5):414-21
pubmed: 21056868
Curr Drug Abuse Rev. 2012 Sep;5(3):227-42
pubmed: 22998621
Drug Alcohol Depend. 2014 Oct 1;143:11-21
pubmed: 25176528
J Subst Abuse Treat. 2016 Dec;71:54-57
pubmed: 27776678
J Clin Epidemiol. 2016 Jul;75:40-6
pubmed: 27005575
J Clin Epidemiol. 2014 Dec;67(12):1291-4
pubmed: 25034198
Drug Alcohol Depend. 2019 Jan 1;194:410-429
pubmed: 30502543
J Clin Nurs. 2018 Jul;27(13-14):2569-2582
pubmed: 29679414
J Clin Epidemiol. 2011 Apr;64(4):380-2
pubmed: 21185693
Oral Dis. 2009 Jan;15(1):27-37
pubmed: 18992021
Compr Psychiatry. 2006 May-Jun;47(3):215-20
pubmed: 16635651
BMC Med Res Methodol. 2013 Mar 23;13:48
pubmed: 23522333
Drug Alcohol Depend. 2018 May 1;186:130-137
pubmed: 29573648
Addiction. 2019 Dec;114(12):2122-2136
pubmed: 31328345
J Subst Abuse Treat. 2002 Mar;22(2):103-8
pubmed: 11932136
Cochrane Database Syst Rev. 2016 May 05;(5):CD005336
pubmed: 27149547
AIDS Patient Care STDS. 2012 Jan;26(1):36-52
pubmed: 22070609
BMJ. 2017 Sep 21;358:j4008
pubmed: 28935701
PLoS One. 2017 Feb 16;12(2):e0172560
pubmed: 28207902
Addiction. 2012 Jul;107(7):1297-306
pubmed: 22221594
Res Synth Methods. 2012 Jun;3(2):80-97
pubmed: 26062083
Iran J Psychiatry Behav Sci. 2015 Mar;9(1):e216
pubmed: 26251659
J Drug Issues. 2013 Oct;43(4):468-482
pubmed: 26594058
BMC Psychiatry. 2012 Dec 05;12:221
pubmed: 23216941
Iran J Psychiatry Behav Sci. 2015 Mar;9(1):e222
pubmed: 26251660
J Psychiatr Res. 2016 Jan;72:1-5
pubmed: 26519763
Int J Offender Ther Comp Criminol. 2010 Dec;54(6):915-36
pubmed: 19910511
Syst Rev. 2015 Jan 01;4:1
pubmed: 25554246
Syst Rev. 2016 Nov 14;5(1):189
pubmed: 27842569
J Addict Dis. 2015;34(1):88-100
pubmed: 25415384
Ann Intern Med. 2018 Oct 2;169(7):467-473
pubmed: 30178033
Addiction. 2014 May;109(5):798-806
pubmed: 24400972
Addict Health. 2014 Summer-Autumn;6(3-4):146-54
pubmed: 25984282
PLoS Med. 2018 Dec 26;15(12):e1002715
pubmed: 30586362
Drug Alcohol Depend. 2013 May 1;129(3):167-79
pubmed: 23273775
Neuropharmacology. 2009 Mar;56(4):752-60
pubmed: 19136017
Cochrane Database Syst Rev. 2015 May 27;(5):CD003352
pubmed: 26014366
Drug Alcohol Depend. 2010 Feb 1;107(1):23-30
pubmed: 19836904
Syst Rev. 2014 Jun 23;3:60
pubmed: 24956937
Curr Opin Pharmacol. 2005 Feb;5(1):107-18
pubmed: 15661634
Neurosci Lett. 2005 Aug 12-19;384(1-2):76-81
pubmed: 15913890
Ann N Y Acad Sci. 2004 Oct;1025:279-87
pubmed: 15542728
Cochrane Database Syst Rev. 2013 Sep 02;(9):CD009695
pubmed: 23996457
Addiction. 2010 May;105(5):916-9
pubmed: 20148788
Addiction. 2013 Apr;108(4):751-61
pubmed: 23186131
West J Med. 1998 Feb;168(2):93-7
pubmed: 9499742
Pharmacopsychiatry. 2018 Nov;51(6):243-250
pubmed: 29334687
Riv Psichiatr. 2018 Sep-Oct;53(5):233-255
pubmed: 30353199
Front Neurosci. 2015 Apr 29;9:151
pubmed: 25972781
Expert Rev Clin Pharmacol. 2017 Mar;10(3):305-314
pubmed: 27927042
Cochrane Database Syst Rev. 2010 Feb 17;(2):CD007380
pubmed: 20166094
Drug Alcohol Rev. 2008 May;27(3):309-17
pubmed: 18368613
J Interpers Violence. 2006 Apr;21(4):435-45
pubmed: 16501213
J Subst Abuse Treat. 2005 Sep;29(2):67-74
pubmed: 16135335
Drug Alcohol Depend. 2002 Jun 1;67(1):13-26
pubmed: 12062776
Am J Psychiatry. 2008 Nov;165(11):1442-8
pubmed: 18765480

Auteurs

C Hamel (C)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada.

K Corace (K)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada.
Substance Use and Concurrent Disorders Program, The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada.
Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada.

M Hersi (M)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada.

D Rice (D)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada.
Department of Psychology, McGill University, Montreal, Quebec, Canada.

M Willows (M)

Substance Use and Concurrent Disorders Program, The Royal Ottawa Mental Health Centre, Ottawa, Ontario, Canada.
Department of Psychiatry, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada.
Department of Family Medicine, Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

P Macpherson (P)

Division of Infectious Diseases, The Ottawa Hospital, Ottawa, ON, Canada.
Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.

B Sproule (B)

Department of Pharmacy, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Leslie Dan Faculty of Pharmacy and Department of Psychiatry, University of Toronto, Toronto, ON, Canada.

J Flores-Aranda (J)

Université du Quebec, Montreal, QC, Canada.

G Garber (G)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada.
School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada.
Public Health Ontario, Toronto, ON, Canada.

L Esmaeilisaraji (L)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada.

B Skidmore (B)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada.

A Porath (A)

Canadian Center on Substance Use and Addiction, Ottawa, ON, Canada.

R Ortiz Nunez (R)

Max Ottawa, Ottawa, ON, Canada.

B Hutton (B)

Center for Practice Changing Research, Ottawa Hospital Research Institute, The Ottawa Hospital, General Campus, 501 Smyth Road, Box 201b, Ottawa, Ontario, K1H 8 L6, Canada. bhutton@ohri.ca.
Institute of Mental Health Research, University of Ottawa, Ottawa, Ontario, Canada. bhutton@ohri.ca.
School of Epidemiology, Public Health and Preventive Medicine, University of Ottawa, Ottawa, ON, Canada. bhutton@ohri.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH